Literature DB >> 2743325

Cancer risk in relation to serum copper levels.

R J Coates1, N S Weiss, J R Daling, R L Rettmer, G R Warnick.   

Abstract

A nested, matched case-control study was conducted to assess the relationship between serum levels of copper and the subsequent risk of cancer. One hundred thirty-three cases of cancer were identified during 1974-1984 among 5000 members of a northwest Washington State employee cohort from whom serum specimens had been previously obtained and stored. Two hundred forty-one controls were selected at random from the cohort and were matched to the cases on the basis of age, sex, race, and date of blood draw. Serum copper levels were measured by atomic absorption spectrometry. Risk of a subsequent diagnosis of cancer was positively associated with serum copper levels, but only among those cases diagnosed within 4 years of the time the serum specimens were collected. Among cases diagnosed more than 4 years after specimen collection, there was no consistent association between serum copper levels and risk. Adjustment for age, sex, race, occupational status, cigarette smoking, family history of cancer, alcohol consumption, and, among females, use of exogenous hormones had no appreciable effect on these relationships. The findings suggest that the presence of cancer may increase serum copper levels several years prior to its diagnosis. They are less supportive of the hypothesis that serum copper levels affect cancer risk.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2743325

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.

Authors:  F Wang; P Jiao; M Qi; M Frezza; Q P Dou; B Yan
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 2.  Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma.

Authors:  Sarah Sammons; Donita Brady; Linda Vahdat; April Ks Salama
Journal:  Melanoma Manag       Date:  2016-09-02

Review 3.  Copper transporters and copper chaperones: roles in cardiovascular physiology and disease.

Authors:  Tohru Fukai; Masuko Ushio-Fukai; Jack H Kaplan
Journal:  Am J Physiol Cell Physiol       Date:  2018-06-06       Impact factor: 4.249

4.  Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.

Authors:  Steven Brem; Stuart A Grossman; Kathryn A Carson; Pamela New; Surasak Phuphanich; Jane B Alavi; Tom Mikkelsen; Joy D Fisher
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

Review 5.  The role of copper in tumour angiogenesis.

Authors:  Sarah A Lowndes; Adrian L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

6.  Dual role of selected antioxidants found in dietary supplements: crossover between anti- and pro-oxidant activities in the presence of copper.

Authors:  Jun-Jie Yin; Peter P Fu; Herman Lutterodt; Yu-Ting Zhou; William E Antholine; Wayne Wamer
Journal:  J Agric Food Chem       Date:  2012-02-28       Impact factor: 5.279

7.  Copper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma.

Authors:  Ye-Jin Kim; Gavin J Bond; Tiffany Tsang; Jessica M Posimo; Luca Busino; Donita C Brady
Journal:  Metallomics       Date:  2019-07-18       Impact factor: 4.526

Review 8.  Copper and angiogenesis: unravelling a relationship key to cancer progression.

Authors:  Lydia Finney; Stefan Vogt; Tohru Fukai; David Glesne
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-05-23       Impact factor: 2.557

9.  Gelsolin and ceruloplasmin as potential predictive biomarkers for cervical cancer by 2D-DIGE proteomics analysis.

Authors:  Ilambarthi Lokamani; Mee-Lee Looi; Siti Aishah Md Ali; Ahmad Zailani Hatta Mohd Dali; Muhammad Azrif Ahmad Annuar; Rahman Jamal
Journal:  Pathol Oncol Res       Date:  2013-08-08       Impact factor: 3.201

10.  Serum ceruloplasmin and the risk of cancer in Finland.

Authors:  P Knekt; A Aromaa; J Maatela; A Rissanen; M Hakama; R K Aaran; T Nikkari; T Hakulinen; R Peto; L Teppo
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.